NCT05127122撤回1 期
Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles Infusion Treatment for Acute Respiratory Distress Syndrome: A Phase I/II Clinical Trial
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 主要终点
- The incidence of serious adverse events.
研究概览
简要总结
To evaluate the safety and efficacy of intravenous(IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles(EV), ExoFlo, as treatment for Acute Respiratory Distress Syndrome.
详细描述
To evaluate the safety and efficacy of intravenous(IV) administration of bone marrow mesenchymal stem cell-derived extracellular vesicles (EV), ExoFlo, as treatment for Acute Respiratory Distress Syndrome. ExoFlo is also referred to as Investigational Product (IP) throughout the protocol. The duration of the study is 60 days, and the endpoints are as follows:
Primary Endpoint:
- The incidence of serious adverse events.
- All-Cause Mortality at 28 days.
Secondary Endpoints:
- Ventilator-free days at 28days.
- Improvement in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form (either by the individual or by the individual's healthcare proxy).
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Male or female aged 18-
- •Moderate to severe ARDS as defined by modified Berlin definition (See Section 2.2.1), which includes timing within 1 week of known clinical insult or new or worsening respiratory symptoms; bilateral opacities not fully explained by effusions, or lung collapse; respiratory failure not fully explained by cardiac failure or fluid overload; PaO2/FiO2 ≤ 200 mm Hg.
- •Hypoxia requiring noninvasive oxygen support such as Nasal Cannula (NC), Nonrebreather (NRB), Bilevel Positive Airway Pressure (BIPAP), Continuous Positive Airway Pressure (CPAP), high flow nasal cannula oxygen (HFNC O2) or mechanical ventilation (MV) despite initiating standard of care.
- •If the candidate is either a male or female of reproductive potential, he or she must agree to use of double barrier method of highly effective birth control contraception such as condoms with oral contraceptive pill or choose to remain abstinent if already practicing abstinence during the screening period. The required duration of usage of double barrier method OR maintenance of abstinence must include the time from the beginning of the screening period until 90 days following the last dose of the study treatment.
排除标准
- •Vulnerable populations such as pregnant patients, children, individuals with severe physical or mental disabilities who cannot provide meaningful consent.
- •Active malignancy requiring treatment within the last five years.
- •Major physical trauma in the last 2 days, including motor vehicle accidents, assaults, mechanical falls with sequelae of significant bleeding or craniofacial bruising, and surgeries, such that not one or more injury may be undiagnosed at time of screening.
- •Diagnosis or suspected diagnosis of sepsis without basic microbiology cultures (urinalysis, urine culture, two sets of blood cultures, respiratory culture, at least a standard respiratory viral panel PCR) being collected prior to screening. (Note: Standard respiratory viral panel is defined by at least PCR testing for Adenovirus, Influenza A, Influenza B, Parainfluenza 1-3, Rhinovirus/Enterovirus, and RSV.)
- •Duration of mechanical ventilation exceeds 5 days or 120 hours.
- •Severe pre-existing organ dysfunction prior to admission, as evidenced by being currently listed on one or more organ transplant list, or intermittent Hemodialysis (HD) or Peritoneal Dialysis.
- •Presence of severe hematologic disorder or coagulopathy, such as Disseminated Intravascular Coagulopathy, as evidenced by the activation of a Massive Transfusion Protocols (as defined by the rapid administration of packed Red Blood Cells, Fresh Frozen Plasma and Platelets in fixed ratios, including at least 6 packed Red Blood Cells, within a 24 hour period) within 72 hours or frequent thrombosis of catheters (as specified by replacing 2 catheters or more within a 72 hour period of new placement) within 72 hours.
- •Severe anemia or myelodysplastic syndrome requiring more than 10 units of packed Red Blood Cells transfused within the last 12 months.
- •Patient is currently connected to Extracorporal Membrane Oxygenation.
研究组 & 干预措施
Placebo Saline
Placebo Comparator
Saline
干预措施: Saline (Other)
10mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Experimental
ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
干预措施: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (Drug)
15mL Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles
Experimental
ExoFlo (Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles)
干预措施: Bone Marrow Mesenchymal Stem Cell Derived Extracellular Vesicles (Drug)
结局指标
主要结局
The incidence of serious adverse events.
时间窗: 60 days
Number to patients with All-Cause Mortality at 28 days
时间窗: 28 days
次要结局
- Ventilator-free days at 28days(28 days)
- Change in partial pressure of arterial oxygen to fraction of inspired oxygen (PaO2/FiO2) ratio from pre-infusion baseline(Day 0)to Day 7.PaO2 may be calculated from arterial blood gas (ABG)or imputed from the SpO2daily.(7 days)
研究者
相似试验
招募中
3 期
Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)ARDSAcute Respiratory Distress SyndromeNCT05354141Direct Biologics, LLC970
已完成
2 期
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDSCOVID-19ARDSNCT04493242Direct Biologics, LLC102
撤回
1 期
ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 SyndromeCovid19Postviral SyndromeDyspneaNCT05116761Direct Biologics, LLC60
已完成
1 期
Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Chronic Kidney DiseaseChronic Kidney DiseasesNCT05362786LaTonya J. Hickson14
Unknown
1 期
Mesenchymal Stem Cells Transplantation to Patients With Relapsed/Refractory Aplastic Anemia.Aplastic AnemiaNCT01305694Guangzhou General Hospital of Guangzhou Military Command50